Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.52 |
| ▸ | POLB | P06746 | 7/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.52 |
| ▸ | CDC25A | P30304 | 3/20 | 0.52 |
| ▸ | CDC25B | P30305 | 3/20 | 0.52 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19509009 | 0.84 | ALDH1A1 (0.47) | MAPTALDH1A1POLBKDM4ELMNA | |
| SCHEMBL17835129 | 0.79 | MAPT (0.45) | MAPTALDH1A1POLBKDM4ELMNA | |
| SCHEMBL9628046 | 0.76 | MAPT (0.68) | MAPTALDH1A1POLBKDM4ELMNA | |
| SCHEMBL571557 | 0.71 | MAPT (1.00) | MAPTALDH1A1POLBKDM4ELMNA | |
| SCHEMBL29545010 | 0.71 | MAPT (1.00) | MAPTALDH1A1POLBKDM4ELMNA | |
| SCHEMBL20153930 | 0.71 | MAPT (0.42) | MAPTALDH1A1POLBKDM4ELMNA | |
| SCHEMBL9627635 | 0.70 | MAPT (0.59) | MAPTALDH1A1POLBKDM4ELMNA | |
| SCHEMBL17520519 | 0.69 | ALDH1A1 (0.44) | MAPTALDH1A1POLBKDM4ELMNA | |
| SCHEMBL21232268 | 0.68 | MAPT (0.50) | MAPTALDH1A1POLBKDM4ELMNA | |
| Anthraquinone SCHEMBL29674372 | 0.67 | KEAP1 (0.50) | MAPTALDH1A1POLBKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11160770-B2 | Compounds, compositions and methods for treating oxidative DNA damage disorders | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200215001-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OXIDATIVE DNA DAMAGE DISORDERS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2020-07-09 | — | — | US | disclosed |
| US-20170304222-A1 | Compounds, Compositions and Methods for Treating Oxidative DNA Damage Disorders | INDIANA UNIV AND RES TECH CORP (US) | 2017-10-26 | — | — | US | disclosed |
| US-20160166521-A1 | Compounds, Compositions and Methods for Treating Oxidative DNA Damage Disorders | INDIANA UNIVERSITY AND RES TECHNOLOGY CORP (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160045461-A1 | QUINONE COMPOUNDS FOR TREATING APE1 MEDIATED DISEASES | APEXIAN PHARMACEUTICALS, INC. | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200215001-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OXIDATIVE DNA DAMAGE DISORDERS | OGG1, UNG, ERCC4 | MAPT 2382/4885ALDH1A1 291/4885POLB 11/4885 |
| US-20170304222-A1 | Compounds, Compositions and Methods for Treating Oxidative DNA Damage Disorders | OGG1, UNG, ERCC4 | MAPT 2382/4885ALDH1A1 291/4885POLB 11/4885 |
| US-20160166521-A1 | Compounds, Compositions and Methods for Treating Oxidative DNA Damage Disorders | OGG1, UNG, ERCC4 | MAPT 2468/4885ALDH1A1 303/4885POLB 10/4885 |
| US-11160770-B2 | Compounds, compositions and methods for treating oxidative DNA damage disorders | OGG1, UNG, ERCC4 | MAPT 2382/4885ALDH1A1 291/4885POLB 11/4885 |
| US-20160045461-A1 | QUINONE COMPOUNDS FOR TREATING APE1 MEDIATED DISEASES | NQO1, APEX1, KEAP1 | MAPT 1164/4885ALDH1A1 528/4885POLB 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.